scholarly journals Effects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Elderly Body Composition and Muscle Strength: A Review of Clinical Trials

2021 ◽  
pp. 1-7
Author(s):  
Nicolas de Angelus Costa Riela ◽  
Maiara Moeme Alvim Guimarães ◽  
Daniela Oliveira de Almeida ◽  
Edilene Maria Queiroz Araujo

Background: The aging process has great impact on body composition, such as the increase of adipose tissue in abdominal region, and the decrease of lean body mass, due to skeletal muscle loss. A reduction in muscle mass is associated to high risk of fractures and falls, loss of mobility, and increased number of hospitalizations. Beta-hydroxy-beta-methylbutyrate (HMB) is a biological substance derived from leucine metabolism, with anabolic and anticatabolic properties. Some HMB effects are tissue repair stimulation and protein anabolism. Aims: We aimed to evaluate the effects of HMB supplementation on body composition and muscle strength in elderly, as well as to identify the efficient dosages to reach these effects. Methods: This review included studies that evaluated muscle mass and muscle strength, associated or not with physical exercise and diet in elderly people. Only studies published from 2008 to 2019 were selected for analysis. Results: Six articles were included in the review. The used doses varied from 1.5 to 3 g. In 5 studies, HMB supplementation was associated with calcium; only 1 study did not use the oral administration route. Two studies used 4 g of maltodextrin as a vehicle; 1 used HMB with a hypercaloric and hyperproteic supplement; 1 associated HMB with lysine and arginine; and 1 with arginine and glutamine. Supplementation of 3 g of HMB has shown to be most beneficial in improving strength and body composition in people over 65 years, especially in bed rest and untrained conditions. Conclusion: Our findings suggest that HMB has a positive effect on body composition and strength, especially in bedridden or sedentary elderly, due to its anticatabolic properties.

2020 ◽  
Vol 40 ◽  
pp. 446
Author(s):  
F. Carrasco ◽  
P. Rojas ◽  
G. Carrasco ◽  
K. Basfi-fer ◽  
M. Manriquez ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3603-3603 ◽  
Author(s):  
Alina S. Gerrie ◽  
Pamela Plantinga ◽  
Kei Nishikawa ◽  
Stanley Hung ◽  
Jennifer Kadgien ◽  
...  

Abstract Background: There is compelling evidence that physical activity positively influences quality of life (QoL), and health-related outcomes including improved muscle mass and physical functioning in cancer pts. SCT pts however have unique barriers to exercise including isolation, restriction of activities, and treatment toxicity. In the early post SCT period, pts describe worsening fatigue, physical capacity and QoL. We sought to determine whether a partially supervised exercise intervention early post SCT would address these issues. Our primary objective was to determine the feasibility of delivering such an intervention at our institution. Secondary objectives were to assess changes as a result of the intervention in QoL, muscle mass and physical functioning. Methods: From Aug 2015-Jun 2016, we conducted a prospective single-arm study to evaluate feasibility of a 12 week partially supervised exercise program (1 supervised, 2 unsupervised sessions/week) for alloSCT pts with hematologic malignancies. The program consisted of 3 progressive endurance (stationary bike, walking) and 2 resistance training sessions/week, from hospital discharge (D/C) to Day (D) 100. Feasibility was defined as ability to recruit >65% of eligible pts, ≥70% retention and ≥70% adherence. Secondary outcomes were measured pre SCT (T0), at D/C (T1) and D100 (T2) and included QoL, muscle strength, mobility, aerobic fitness and body composition. Changes from T0 to T1 and T1 to T2 were compared using a paired sample t-test. Results: Of 43 consecutive alloSCT pts assessed for eligibility, 30 (70%) entered the study: 17 male (57%), median age 48 yrs (range 19-66 yrs). Transplants characteristics were: related 6; unrelated 24; myeloablative 23; reduced intensity 7. At baseline, SCT comorbidity index was 0 in 43%, 1-2 37%, ≥ 3 20%. Pts self-reported exercising enough to break a sweat (Godin et al) never 60%, sometimes 33%, often 7%. Median hospitalization was 29d (range 15-141); 9 pts developed grade II-IV acute graft-versus-host disease (skin 7, gut 5, liver 1). Overall retention to D100 was 80% (Figure 1). Two pts had complications during hospitalization and did not enter the program. Of the 24 pts who entered the program, adherence was 72% for supervised and 89% for unsupervised sessions. Logistics with scheduling around multiple medical appointments in the early post SCT period were the most common reasons for non-adherence. Other reasons included nausea, fatigue and weakness. One pt developed exercise-induced atrial fibrillation in week 3 requiring cessation of exercise. When comparing secondary outcomes from T0 to T1 (Table 1), pts had significantly decreased muscle strength (grip strength, 30-second chair stand), mobility (timed up-and-go [TUG]) and aerobic capacity (6-min walk test [6MWT]). At T2 after completion of the program, these measures all increased significantly when compared to T1. Global QoL scores on the EORTC measure decreased from T0 to T1 (P=.011) and were significantly improved by T2 (P<.001). Similar trends were seen across functional and symptom measure scales. Body composition comparisons between T0 and T2 demonstrated a trend towards increased appendicular lean mass (P<.059). Conclusion: Results of this pilot study demonstrate feasibility of a partially supervised exercise program post-alloSCT deemed by achieving the target recruitment rate, ≥70% adherence and ≥70% retention. Logistics were the most common reason for non-adherence, highlighting need for a multidisciplinary team with knowledge of the post SCT setting. Prior observational studies have shown significant declines in physical functioning and QoL within the first 100 days of SCT. In contrast we demonstrate significant improvements in these measures. Furthermore, we demonstrate a trend towards increased lean muscle mass, which is a novel secondary outcome that warrants further evaluation in this setting. Our findings support the need for this clinical intervention and will be evaluated in a larger randomized trial. Disclosures Gerrie: Roche Canada: Research Funding. Plantinga:BCCA: Employment. Broady:Lotte & John Hecht Memorial Foundation: Research Funding.


2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Fábio Lera Orsatti ◽  
Eliana Aguiar Petri Nahas ◽  
Jorge Nahas-Neto ◽  
Nailza Maesta ◽  
Cláudio Lera Orsatti ◽  
...  

Objective. To investigate the independent and additive effects of resistance training (RT) and soy isoflavone (ISO) on body composition in postmenopausal women (PW).Method. This study used a placebo-controlled, double-blind (soy), randomized (ISO versus placebo) × (RT versus No RT) design. A total of 80 PW, aged 45–70 years, were randomly (71 completed 9-months intervention): RT + ISO (n=15), No RT + ISO (n=20), RT + placebo (n=18), and No RT + placebo (n=18). ISO received 100 mg a day of isoflavone; and to RT attended supervised resistance training sessions. At baseline and 9-months, fat and muscle mass were estimated by DXA. ANOVA and testtwere used.Results. RT groups showed significantly increased muscle strength (35.2%) and muscle mass (1.4%). Exercising attenuated gains in fat trunk and % body fat (P<.05). Significant decreases in muscle mass (−1.8%) and increases in fat mass of the whole-body (1.6%) and trunk (9.7%) was found in no-RT groups (P<.05). In ISO groups, there were no differences in body composition and muscle strength. ISO and RT had no additive effects.Conclusion. In PW: RT improved muscle mass and strength and attenuated gain of fat mass; ISO did not alter body composition and muscle strength; there were no additive effects of RT and ISO.


2015 ◽  
Vol 114 (8) ◽  
pp. 1237-1245 ◽  
Author(s):  
Denise Zdzieblik ◽  
Steffen Oesser ◽  
Manfred W. Baumstark ◽  
Albert Gollhofer ◽  
Daniel König

AbstractProtein supplementation in combination with resistance training may increase muscle mass and muscle strength in elderly subjects. The objective of this study was to assess the influence of post-exercise protein supplementation with collagen peptidesv.placebo on muscle mass and muscle function following resistance training in elderly subjects with sarcopenia. A total of fifty-three male subjects (72·2 (sd4·68) years) with sarcopenia (class I or II) completed this randomised double-blind placebo-controlled study. All the participants underwent a 12-week guided resistance training programme (three sessions per week) and were supplemented with either collagen peptides (treatment group (TG)) (15 g/d) or silica as placebo (placebo group (PG)). Fat-free mass (FFM), fat mass (FM) and bone mass (BM) were measured before and after the intervention using dual-energy X-ray absorptiometry. Isokinetic quadriceps strength (IQS) of the right leg was determined and sensory motor control (SMC) was investigated by a standardised one-leg stabilisation test. Following the training programme, all the subjects showed significantly higher (P<0·01) levels for FFM, BM, IQS and SMC with significantly lower (P<0·01) levels for FM. The effect was significantly more pronounced in subjects receiving collagen peptides: FFM (TG +4·2 (sd2·31) kg/PG +2·9 (sd1·84) kg;P<0·05); IQS (TG +16·5 (sd12·9) Nm/PG +7·3 (sd13·2) Nm;P<0·05); and FM (TG –5·4 (sd3·17) kg/PG –3·5 (sd2·16) kg;P<0·05). Our data demonstrate that compared with placebo, collagen peptide supplementation in combination with resistance training further improved body composition by increasing FFM, muscle strength and the loss in FM.


2015 ◽  
Vol 12 (9) ◽  
pp. 10558-10574 ◽  
Author(s):  
Roma Krzymińska-Siemaszko ◽  
Natasza Czepulis ◽  
Marta Lewandowicz ◽  
Ewa Zasadzka ◽  
Aleksandra Suwalska ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e042786
Author(s):  
Rikke S Kamper ◽  
Martin Schultz ◽  
Sofie K Hansen ◽  
Helle Andersen ◽  
Anette Ekmann ◽  
...  

IntroductionSarcopenia is generally used to describe the age-related loss of muscle mass and strength believed to play a major role in the pathogenesis of physical frailty and functional impairment that may occur with old age. The knowledge surrounding the prevalence and determinants of sarcopenia in older medical patients is scarce, and it is unknown whether specific biomarkers can predict physical deconditioning during hospitalisation. We hypothesise that a combination of clinical, functional and circulating biomarkers can serve as a risk stratification tool and can (i) identify older acutely ill medical patients at risk of prolonged hospital stays and (ii) predict changes in muscle mass, muscle strength and function during hospitalisation.Method and analysisThe Copenhagen PROTECT study is a prospective cohort study consisting of acutely ill older medical patients admitted to the acute medical ward at Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark. Assessments are performed within 24 hours of admission and include blood samples, body composition, muscle strength, physical function and questionnaires. A subgroup of patients transferred to the Geriatric Department are included in a smaller geriatric cohort and have additional assessments at discharge to evaluate the relative change in circulating biomarker concentrations, body composition, muscle strength and physical function during hospitalisation. Enrolment commenced 4 November 2019, and proceeds until August 2021.Ethics and disseminationThe study protocol has been approved by the local ethics committee of Copenhagen and Frederiksberg (H-19039214) and the Danish Data Protection Agency (P-2019-239) and all experimental procedures were performed in accordance with the Declaration of Helsinki. Findings from the project, regardless of the outcome, will be published in relevant peer-reviewed scientific journals in online (www.clinicaltrials.gov).Trial registration numberNCT04151108


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Nana Takao ◽  
Satoshi Kurose ◽  
Takumi Miyauchi ◽  
Katsuko Onishi ◽  
Atsuko Tamanoi ◽  
...  

Abstract Background An effective strategy for weight loss in patients who are overweight or obese is to reduce body fat mass while maintaining skeletal muscle mass. Adiponectin and myostatin are affected through changes in body composition due to weight loss, and examining their dynamics may contribute to strategies for maintaining skeletal muscle mass through weight loss. We aimed to examine the relationships among myostatin, adiponectin, and body composition, depending on the extent of weight loss, in patients with obesity undergoing a weight loss program. Methods We examined 66 patients with obesity (age: 46.8 ± 14.0 years, body mass index: 34.3 [31.0–38.4] kg/m2) attending a hospital weight loss program. We categorized the patients into two groups, namely an L group (those with a weight reduction of < 5% from baseline) and an M group (those with a weight reduction of > 5% from baseline). All patients underwent blood tests and were assessed for body composition, insulin resistance, adipocytokine and myokine levels, exercise tolerance, and muscle strength at baseline and post-intervention. Results Serum myostatin and adiponectin levels increased post-intervention in both groups. Body weight and %fat decreased, and the rate of lean body mass (%LBM) increased in both groups. Exercise capacity and muscle strength improved in the M group only. Change in (⊿) myostatin correlated with ⊿%fat, ⊿%LBM, and ⊿adiponectin. ⊿adiponectin (β = − 0.262, p = 0.035) was an independent predictor of ⊿myostatin. Conclusions Myostatin and adiponectin might cross-talk and regulate changes in skeletal muscle and fat mass with or without successful weight loss. These findings indicate that evaluating serum myostatin and adiponectin levels in clinical practice could be used to predict the effects of weight loss and help prevent skeletal muscle mass loss.


PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0250439
Author(s):  
Anne N. Hiol ◽  
Pamela R. von Hurst ◽  
Cathryn A. Conlon ◽  
Owen Mugridge ◽  
Kathryn L. Beck

Background Aging is associated with decreases in muscle strength and simultaneous changes in body composition, including decreases in muscle mass, muscle quality and increases in adiposity. Methods Adults (n = 369; 236 females) aged 65–74 years living independently were recruited from the cross-sectional Researching Eating Activity and Cognitive Health (REACH) study. Body fat percentage and appendicular skeletal muscle mass (ASM) (sum of lean mass in the arms and legs) were assessed using Dual-energy X-ray Absorptiometry (Hologic, QDR Discovery A). The ASM index was calculated by ASM (kilograms) divided by height (meters) squared. Isometric grip strength was measured using a hand grip strength dynamometer (JAMAR HAND). Results Linear regression analyses revealed that muscle strength was positively associated with the ASM index (R2 = 0.431, p < 0.001). When exploring associations between muscle strength and muscle mass according to obesity classifications (obesity ≥30% males; ≥40% females), muscle mass was a significant predictor of muscle strength in non-obese participants. However, in participants with obesity, muscle mass was no longer a significant predictor of muscle strength. Conclusions Body fat percentage should be considered when measuring associations between muscle mass and muscle strength in older adults.


Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3101
Author(s):  
Emanuele Rinninella ◽  
Marco Cintoni ◽  
Pauline Raoul ◽  
Carmelo Pozzo ◽  
Antonia Strippoli ◽  
...  

In cancer patients, loss of muscle mass is significantly associated with low tolerability of chemotherapy and poor survival. Despite the great strides in the treatment of cancer, targeted therapies such as tyrosine kinase inhibitors (TKIs) could exacerbate muscle wasting. Over recent years, the impact of skeletal muscle loss during TKI therapy on clinical outcomes has been in the spotlight. In this review, we focus on the different molecular pathways of TKIs potentially involved in muscle wasting. Then, we report the results of the studies assessing the effects of different TKI therapies—such as sorafenib, regorafenib, sunitinib, and lenvatinib—on muscle mass, and highlight their potential clinical implications. Finally, we discuss an integrative nutritional approach to be adopted during TKI treatment. The assessment of muscle mass from computerized tomography imaging could be helpful in predicting toxicity and prognosis in patients treated with TKI such as sorafenib. Early recognition of low muscle mass and effective personalized nutritional support could prevent or attenuate muscle mass wasting. However, the role of nutrition is still overlooked, and future clinical trials are needed to find the optimal nutritional support to countermeasure muscle mass depletion during TKI therapy.


Sign in / Sign up

Export Citation Format

Share Document